Ryom, Lene; De Miguel, Rosa; Cotter, Aoife Grace; Podlekareva, Daria; Béguelin, Charles; Waalewijn, Hylke; Arribas, Josè R; Mallon, Patrick W G; Marzolini, Catia; Kirk, Ole; Bamford, Alasdair; Rauch, Andri; Molina, Jean Michel; Kowalska, Justyna Dominika; Guaraldi, Giovanni; Winston, Alan; Boesecke, Christoph; Cinque, Paola; Welch, Steven; Collins, Simon; ... (2022). Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV medicine, 23(8), pp. 849-858. Wiley 10.1111/hiv.13268
|
Text
HIV_Medicine_-_2022_-_Ryom_-_Major_revision_version_11_0_of_the_European_AIDS_Clinical_Society_Guidelines_2021.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (163kB) | Preview |
BACKGROUND
The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV care.
KEY POINTS OF THE GUIDELINES UPDATE
Version 11.0 of the Guidelines recommend six first-line treatment options for antiretroviral treatment (ART)-naïve adults: tenofovir-based backbone plus an unboosted integrase inhibitor or plus doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. Recommendations on preferred and alternative first-line combinations from birth to adolescence were included in the new paediatric section made with Penta. Long-acting cabotegravir plus rilpivirine was included as a switch option and, along with fostemsavir, was added to all drug-drug interaction (DDI) tables. Four new DDI tables for anti-tuberculosis drugs, anxiolytics, hormone replacement therapy and COVID-19 therapies were introduced, as well as guidance on screening and management of anxiety disorders, transgender health, sexual health for women and menopause. The sections on frailty, obesity and cancer were expanded, and recommendations for the management of people with diabetes and cardiovascular disease risk were revised extensively. Treatment of recently acquired hepatitis C is recommended with ongoing risk behaviour to reduce transmission. Bulevirtide was included as a treatment option for the hepatitis Delta virus. Drug-resistant tuberculosis guidance was adjusted in accordance with the 2020 World Health Organization recommendations. Finally, there is new guidance on COVID-19 management with a focus on continuance of HIV care.
CONCLUSIONS
In 2021, the EACS Guidelines were updated extensively and broadened to include new sections. The recommendations are available as a free app, in interactive web format and as an online pdf.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Béguelin, Charles Antoine, Rauch, Andri |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1468-1293 |
Publisher: |
Wiley |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
28 Mar 2022 08:29 |
Last Modified: |
05 Dec 2022 16:17 |
Publisher DOI: |
10.1111/hiv.13268 |
PubMed ID: |
35338549 |
Uncontrolled Keywords: |
COVID-19 European AIDS Clinical Society (EACS) Guidelines HIV Penta antiretroviral treatment children comorbidities drug-drug interactions hepatitis B virus hepatitis C virus opportunistic infections |
BORIS DOI: |
10.48350/168176 |
URI: |
https://boris.unibe.ch/id/eprint/168176 |
Actions (login required)
 |
Edit item |